Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 30924492.
- Also identified by DOI 10.1093/cid/ciy982 and PMC identifier 6579954.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In a randomized, double-blind, placebo-controlled trial of tenofovir disoproxil fumarate (TDF) use from 28 weeks gestational age to 2 months postpartum to prevent mother-to-child transmission of hepatitis B virus, there was no significant effect of maternal TDF use on maternal or infant bone mineral density 1 year after delivery/birth. Clinical Trials Registration. NCT01745822.
Medical subject headings
- Antiviral Agents
- Bone Density
- Hepatitis B
- Infectious Disease Transmission, Vertical
- Tenofovir